Future Financial Wealth Managment LLC Buys New Stake in Humana Inc. (NYSE:HUM)

Future Financial Wealth Managment LLC purchased a new position in shares of Humana Inc. (NYSE:HUM) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 500 shares of the insurance provider’s stock, valued at approximately $173,000.

Other institutional investors also recently added to or reduced their stakes in the company. Barlow Wealth Partners Inc. acquired a new stake in Humana in the 4th quarter valued at $1,977,000. Auxano Advisors LLC bought a new position in shares of Humana during the fourth quarter valued at $540,000. Intech Investment Management LLC boosted its stake in shares of Humana by 46.2% in the 4th quarter. Intech Investment Management LLC now owns 42,287 shares of the insurance provider’s stock valued at $19,359,000 after purchasing an additional 13,356 shares in the last quarter. AdvisorShares Investments LLC bought a new stake in shares of Humana in the 4th quarter worth about $421,000. Finally, Vest Financial LLC grew its holdings in shares of Humana by 43.3% in the 4th quarter. Vest Financial LLC now owns 27,993 shares of the insurance provider’s stock worth $12,815,000 after purchasing an additional 8,455 shares during the last quarter. 92.38% of the stock is owned by institutional investors and hedge funds.

Humana Price Performance

HUM opened at $362.98 on Friday. The stock has a market cap of $43.74 billion, a P/E ratio of 22.60, a P/E/G ratio of 2.09 and a beta of 0.53. Humana Inc. has a 12 month low of $298.61 and a 12 month high of $530.54. The company has a quick ratio of 1.67, a current ratio of 1.67 and a debt-to-equity ratio of 0.77. The company has a fifty day simple moving average of $342.12 and a 200 day simple moving average of $353.32.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.12 by $1.11. Humana had a return on equity of 17.76% and a net margin of 1.82%. The business had revenue of $29.61 billion during the quarter, compared to analysts’ expectations of $28.52 billion. During the same period in the prior year, the business earned $9.38 EPS. Humana’s revenue for the quarter was up 10.7% compared to the same quarter last year. On average, research analysts expect that Humana Inc. will post 16.27 EPS for the current year.

Humana Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be paid a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 0.98%. The ex-dividend date is Friday, June 28th. Humana’s dividend payout ratio is 22.04%.

Analysts Set New Price Targets

A number of research firms have commented on HUM. Wells Fargo & Company reduced their price target on shares of Humana from $413.00 to $350.00 and set an “overweight” rating on the stock in a research report on Monday, April 8th. Morgan Stanley assumed coverage on Humana in a research report on Monday. They set an “equal weight” rating and a $374.00 price target on the stock. Royal Bank of Canada cut their price objective on Humana from $415.00 to $353.00 and set an “outperform” rating for the company in a research report on Thursday, April 25th. TD Cowen reduced their price objective on Humana from $427.00 to $396.00 and set a “buy” rating on the stock in a research note on Tuesday, April 2nd. Finally, Barclays lowered their target price on Humana from $356.00 to $310.00 and set an “equal weight” rating for the company in a research note on Tuesday, April 2nd. Fourteen research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $409.55.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.